Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8933 USD | +10.82% | +21.87% | +10.28% |
04-25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
04-25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
Evolution of the average Target Price on HOOKIPA Pharma Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering HOOKIPA Pharma Inc.
RBC Capital Markets | |
HC Wainwright | |
Morgan Stanley | |
Truist Securities | |
SVB Securities LLC | |
Kempen | |
SVB Leerink | |
JMP Securities |
EPS Revisions
- Stock Market
- Equities
- HOOK Stock
- Consensus HOOKIPA Pharma Inc.